Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0E8IZ
|
||||
Former ID |
DIB003284
|
||||
Drug Name |
Tonabersat
|
||||
Synonyms |
SB-220453; USL-260; 5-HT1d agonist (migraine), Minster; 5-HT1d agonist (migraine), SB
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Epilepsy [ICD10:G40] | Phase 2 | [522123] | ||
Company |
Upsher-smith laboratories
|
||||
Structure |
Download2D MOL |
||||
Formula |
C20H19ClFNO4
|
||||
Canonical SMILES |
[C@@H]1(c2c(OC([C@H]1O)(C)C)ccc(c2)C(=O)C)NC(=O)c1cc(c(<br />cc1)F)Cl
|
||||
CAS Number |
CAS 175013-84-0
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | 5-hydroxytryptamine 1D receptor | Target Info | Agonist | [525903], [551730] | |
References | |||||
Ref 525903 | The potential anti-migraine compound SB-220453 does not contract human isolated blood vessels or myocardium; a comparison with sumatriptan. Cephalalgia. 2000 Jul;20(6):538-45. | ||||
Ref 551730 | Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors. . The Journal of Headache and Pain 201314(Suppl 1):P75. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.